文献速递贫血与红细胞疾病

基因治疗用于输血依赖型非β0/β0基因型β地中海贫血:beti-cel首次真实世界经验

Gene therapy in transfusion-dependent non-β0/β0 genotype β-thalassemia: first real-world experience of beti-cel.
PubMed 文献 · Blood Adv · 2025-01-01

报告2020年1月至2022年3月欧洲beti-cel在研授权期内首次真实世界应用,15例筛查患者中8例接受beti-cel,均在8至59天内实现输血非依赖,治疗后血红蛋白11.3至19.3 g/dL,无死亡,但观察到垂体-性腺内分泌功能障碍及意外后遗症。

要点

  • 8例接受beti-cel的患者均在8至59天内实现输血非依赖,治疗后血红蛋白11.3至19.3 g/dL。
  • 无死亡发生,急性毒性与白消安已知效应一致,3例因HLA抗体导致治疗后血小板管理困难。
  • 随访至24个月,3例女性及5例男性中2例出现垂体-性腺内分泌功能障碍,并观察到多血质、抑郁焦虑和疲劳等意外后遗症。

核心结论

  • 本次真实世界经验印证了beti-cel的疗效和安全性,并提供了该疗法真实世界使用中观察到的不良事件信息。

研究设计与样本

  • 报告beti-cel在欧洲活跃授权期(2020年1月至2022年3月)的首次真实世界应用,对象为年龄≥12岁、非β0/β0基因型且无HLA相合同胞供者的输血依赖型β地中海贫血患者。
  • 15例筛查患者中4例因生育和安全顾虑选择退出,2例因明显肝脏铁过载被排除,1例单采采集失败,8例接受beti-cel治疗。
  • 8例患者均在接受白消安清髓性预处理后输注beti-cel。

主要发现

  • 8例接受beti-cel的患者均在8至59天内实现输血非依赖,治疗后血红蛋白水平范围为11.3至19.3 g/dL。
  • 无死亡发生,但急性毒性与白消安已知效应一致。
  • 3例患者因HLA抗体导致治疗后血小板管理面临挑战。
  • 监测至第24个月,3例女性患者全部及5例男性患者中2例出现垂体-性腺内分泌功能障碍。
  • 观察到意外治疗后后遗症:1例出现无法用已知遗传或获得性机制解释的多血质,1例出现治疗后抑郁和焦虑致其无法重返工作,1例出现严重损害生活质量和劳动能力的疲劳。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gene addition and editing strategies for transfusion-dependent β-thalassemia have gained momentum as potentially curative treatment options, with studies showcasing their efficacy and safety. We report, to our knowledge, the first real-world application of betibeglogene autotemcel (beti-cel; Zynteglo) during its period of active license in Europe from January 2020 to March 2022 for patients aged ≥12 years without a β0/β0 genotype and without a HLA-matched sibling donor, before beti-cel marketing authorization was withdrawn by its holder because of nonsafety reasons. Among 15 screened patients, 4 opted out for fertility and safety concerns, 2 were excluded because of marked hepatic siderosis, and 1 had apheresis collection failure. Eight patients received beti-cel after busulfan myeloablative conditioning, all achieving transfusion independence within 8 to 59 days, with posttreatment hemoglobin levels ranging from 11.3 to 19.3 g/dL. No deaths occurred, but acute toxicity mirrored busulfan's known effects. Posttreatment platelet management faced challenges because of HLA-antibodies in 3 patients. Monitoring up to month 24 revealed pituitary-gonadal endocrine dysfunction in all 3 female and in 2 of 5 male patients. Additionally, we observed unexpected posttreatment sequelae: 1 patient developed polycythemia that could not be explained by known genetic or acquired mechanisms, 1 patient developed posttreatment depression and anxiety prohibiting her from returning to work, and 1 patient developed fatigue severely compromising both quality of life and work capacity. This real-world experience corroborates beti-cel's efficacy and safety and provides information on adverse events observed during real-world use of the therapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Mirza A, Ritsert ML, Tao G, et al. Gene therapy in transfusion-dependent non-β0/β0 genotype β-thalassemia: first real-world experience of beti-cel. Blood Adv. 2025. PMID: 39418614. doi:10.1182/bloodadvances.2024014104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。